Evidence map›Paper›PMID 38638053›Full record

ReviewCurrent pharmaceutical design2024

The Therapeutic Application of Hydrogen in Cancer: The Potential and Challenges.

Morteza Nazari Khiji, Faezeh Arghidash, Ghazaleh Khalili Tanha, Rasoul Hossein Zadeh, Elnaz Ghorbani, Majid Khazaei, Seyed Mahdi Hassanian, Ibrahim Saeed Gataa, Alfred King-Yin Lam, Elisa Giovannetti and 3 more

Open access · goldAbstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 6 countries.

Morteza Nazari KhijiStudent Research Committee, Sabzevar University of Medical Sciences, Sabzevar, Iran.
Faezeh ArghidashDepartment of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Ghazaleh Khalili TanhaMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Rasoul Hossein ZadehStudent Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Elnaz GhorbaniMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid KhazaeiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Seyed Mahdi HassanianMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Ibrahim Saeed GataaCollege of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq.
Alfred King-Yin LamDepartment of Pathology, School of Medicine and Dentistry, Griffith University, Gold Coast Campus, Gold Coast, QLD 4222, Australia.
Elisa GiovannettiCancer Pharmacology Lab, AIRC Start Up Unit, Fondazione Pisana per La Scienza, Pisa, Italy.
Gordon A FernsDivision of Medical Education, Brighton & Sussex Medical School, Falmer, Brighton, Sussex BN1 9PH, UK.
Elham NazariDepartment of Health Information, Technology and Management, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Amir AvanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mashhad University of Medical Sciences · IRAmsterdam UMC Location VUmc · NLBrighton and Sussex Medical School · GBGriffith University · AUQueensland University of Technology · AUSabzevar University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IRUniversity of Warith Al-Anbiyaa

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hydrogen therapy has emerged as a possible approach for both preventing and treating cancer. Cancers are often associated with oxidative stress and chronic inflammation. Hydrogen, with its unique physiological functions and characteristics, exhibits antioxidant, anti-inflammatory, and anti-apoptotic properties, making it an attractive candidate for cancer treatment. Through its ability to mitigate oxidative damage, modulate inflammatory responses, and sustain cellular viability, hydrogen demonstrates significant potential in preventing cancer recurrence and improving treatment outcomes. Preclinical studies have shown the efficacy of hydrogen therapy in several cancer types, highlighting its ability to enhance the effectiveness of conventional treatments while reducing associated side effects. Furthermore, hydrogen therapy has been found to be safe and well-tolerated in clinical settings. Nonetheless, additional investigations are necessary to improve a comprehensive understanding of the mechanisms underlying hydrogen's therapeutic potential and refine the administration and dosage protocols. However, further clinical trials are still needed to explore its safety profile and capacity. In aggregate, hydrogen therapy represents an innovative and promising treatment for several malignancies.

Indexed as

HydrogenNeoplasmsOxidative StressAnimalsAntineoplastic AgentsAntioxidantsHumansAntineoplastic AgentsAntioxidantsHydrogenantioxidantcancerHydrogeninflammation.oxidative stresstherapeutic application

Identifiers

PMID38638053
OpenAlexW4394958781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.